Glioblastoma (GBM) is the most common primary malignant brain tumor in adults.
Regardless of ideal multidisciplinary treatment, including maximal surgical resection …

Introduction Standards of care are not yet defined in recurrent glioblastoma. Methods We
reviewed the literature on clinical trials for recurrent glioblastoma available in PubMed and …

Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, with a
median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a …

Purpose: FGFR genomic alterations (amplification, mutations, and/or fusions) occur in∼ 8%
of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single …

Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with
a poor prognosis. Age, performance status, mini-mental status examination score …

BACKGROUND: The authors performed a phase 2 trial of combined protracted daily
temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had …

Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma
and glioblastoma. Its role in the treatment of recurrent disease has been confirmed, and …

High-grade gliomas represent a significant source of cancer-related death, and usually recur
despite treatment. In this analysis of current brain tumor medicine, we review diagnosis …

Malignant glioma is the most commonly occurring primary malignant brain tumor. It is difficult
to treat and is usually associated with an inexorable, rapidly fatal clinical course …

Background and purpose: Despite the given advances in neuro-oncology most patients with
high grade malignant glioma ultimately fail locally or locoregionally. In parallel with …